Search Results

You are looking at 81 - 90 of 93 items for :

  • "rituximab" x
  • Refine by Access: All Content x
Clear All
Orvosi Hetilap
Authors: Anna Bazsó, Gyula Poór, Péter Gergely, and Emese Kiss

168 Dörner, T., Burmester, G. R.: New approaches of B-cell-directed therapy: beyond rituximab. Curr. Opin. Rheumatol., 2008, 20 , 263

Restricted access

Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H. és mtsai: Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta cell function. N. Engl. J. Med., 2009, 361 , 2143

Open access

Genomikus kópiaszám-eltérések szűrése krónikus limfoid leukémiában multiplex ligációfüggő szondaamplifikációval

Screening for genomic copy number alterations in chronic lymphocytic leukemia using multiplex ligation-dependent probe amplification

Hematológia–Transzfuziológia
Authors: Richárd Kiss, Gergő Papp, Szilvia Krizsán, Lili Kotmayer, Ambrus Gángó, Noémi Nagy, Bence Bátai, Zoltán Mátrai, Csaba Bödör, and Donát Alpár

, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997−1007. 33 Thompson PA, Wierda WG, Ferrajoli A, et al

Restricted access

Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults

A Magyar Infektológiai és Klinikai Mikrobiológiai Társaság Vakcinológiai Szekciójának állásfoglalása (2014. október)

Orvosi Hetilap
Authors: Endre Ludwig and Zsófia Mészner

vaccine in pneumococcal vaccine-naive adults. Vaccine, 2013, 31 (35), 3577–3584. Hua, C., Barnetche, T., Combe, B., et al.: Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response

Open access

responds to B cell depletion therapy with rituximab. Ann. Rheum. Dis., 2012, 71 (1), 75–79. 57 Mayrbaeurl, B., Hinterreiter, M., Burgstaller, S., et al.: The

Restricted access

anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors . Exp Hematol Oncol 2 , 2 ( 2013 ) 19. Banach

Open access
Orvosi Hetilap
Authors: Zoltán Szekanecz, Izabella Gomez, Boglárka Soós, Levente Bodoki, Szilvia Szamosi, Csilla András, Balázs Juhász, László Váróczy, Péter Antal-Szalmás, Péter Szodoray, Nóra Bittner, Péter Árkosy, Árpád Illés, Gabriella Szűcs, Katalin Dankó, Tamás Bender, László Tamási, and Éva Szekanecz

, Frisell T, Askling J, et al. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a

Open access
Orvosi Hetilap
Authors: Klára Gadó and Gyula Domján

), 4060–4069. Scully, M.: Rituximab in the treatment of TTP. Hematology, 2012, 17 (Suppl. 1), S22–S24. Swisher, K. K., Terrell, D. R., Vesely, S. K., et al.: Clinical outcomes

Open access

costs: The rituximab experience. Am. J. Manag. Care, 2003, 9 , 393–400. Fendrick A. M. Effect of off-label use of oncology drugs on pharmaceutical costs: The rituximab experience

Restricted access

mortality [ 1–5 ]. Immunosuppressive therapy has significantly improved the outcome of the disease. Before the 1970s the first-year mortality of patients with systemic AAV was higher than 85%, but corticosteroid and cytotoxic agents, recently rituximab

Open access